Filing Flows › Teladoc Health (TDOC) › Q3 2026 › vs Q2 2026
Teladoc Health (TDOC) Q3 2026 vs Q2 2026 (quarter over quarter)
Teladoc Health's revenue fell $1.8M (-0.3%) from $607M in Q2 2026 to $605M in Q3 2026. The biggest changes: Access Fees −$7.5M (-2%); Other +$5.7M (+4%).
Teladoc Health, Q3 2026: revenue $605M (-3% year over year), operating margin -4.6%, net loss $26.9M, operating cash flow $106M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 17.4% | 10.5% | +6.9 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Access Fees | $467M | $474M | −$7.5M | -2% |
| Other | $138M | $133M | $5.7M | +4% |
| Revenue | $605M | $607M | −$1.8M | -0.3% |
| Other income, net | $1.8M | −$819K | $2.6M | — |
| Net loss | $26.9M | $38.9M | −$12.0M | -31% |
| Costs & expenses | $634M | $646M | −$12.0M | -2% |
| Operating costs | $633M | $644M | −$10.8M | -2% |
| Income tax | $655K | $997K | −$342K | -34% |
| Cost of revenue | $190M | $191M | −$579K | -0.3% |
| Research & development | $65.5M | $62.9M | $2.7M | +4% |
| Sales & marketing | $124M | $143M | −$19.4M | -14% |
| General & admin | $107M | $104M | $3.4M | +3% |
| Other operating costs | $146M | $143M | $3.1M | +2% |
| Operating cash sources | $133M | $104M | $29.8M | +29% |
| Share-based compensation | $11.6M | $9.3M | $2.3M | +25% |
| Working capital & other | $122M | $94.3M | $27.5M | +29% |
| Net loss absorbed | $26.9M | $38.9M | −$12.0M | -31% |
| Operating cash flow | $106M | $64.7M | $41.8M | +65% |
| Free cash flow (OCF − capex) | $105M | $63.7M | $41.5M | +65% |
| Capital expenditures | $1.2M | $928K | $286K | +31% |
Questions
How much did Teladoc Health's revenue grow quarter over quarter in Q3 2026?
Teladoc Health's revenue fell $1.8M (-0.3%) from $607M in Q2 2026 to $605M in Q3 2026.
What drove Teladoc Health's revenue change in Q3 2026?
Access Fees −$7.5M (-2%); Other +$5.7M (+4%).